Could NeoGenomics, Inc. (NEO) Skyrocket Even More? The Stock Just Made 52-Week High

June 20, 2018 - By Vivian Park

NeoGenomics, Inc. (NASDAQ:NEO) Logo

Investors sentiment increased to 1.43 in Q1 2018. Its up 0.60, from 0.83 in 2017Q4. It increased, as 8 investors sold NeoGenomics, Inc. shares while 34 reduced holdings. 19 funds opened positions while 41 raised stakes. 63.35 million shares or 0.63% less from 63.75 million shares in 2017Q4 were reported.
Secor Capital Advisors L P holds 0.1% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 142,350 shares. California State Teachers Retirement Sys owns 85,971 shares. Marshall Wace Llp has invested 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). Howland Capital Limited Com holds 0.01% or 21,782 shares in its portfolio. Moreover, Geode Capital Management Ltd has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO). South State Corporation has invested 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). Renaissance Tech Limited Liability accumulated 0% or 40,100 shares. The Massachusetts-based Cadence Capital Mgmt Lc has invested 0.09% in NeoGenomics, Inc. (NASDAQ:NEO). Rmb Limited Liability owns 808,306 shares. Moreover, Blackrock has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO). Schwab Charles Inc holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 305,995 shares. State Bank Of Mellon has 703,512 shares for 0% of their portfolio. Bluecrest Cap Limited holds 10,295 shares or 0% of its portfolio. 131,791 are held by Tiaa Cref Investment Mgmt. Manufacturers Life The reported 44,227 shares.

Since May 10, 2018, it had 0 insider purchases, and 5 selling transactions for $6.56 million activity. JONES STEVEN C sold 169,467 shares worth $1.98M. 81,999 shares valued at $883,949 were sold by ROSS STEVEN A on Thursday, May 10.

The stock of NeoGenomics, Inc. (NASDAQ:NEO) hit a new 52-week high and has $14.29 target or 6.00 % above today’s $13.48 share price. The 5 months bullish chart indicates low risk for the $1.09B company. The 1-year high was reported on Jun, 20 by If the $14.29 price target is reached, the company will be worth $65.22M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.67% or $0.09 during the last trading session, reaching $13.48. About 352,531 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has risen 53.64% since June 20, 2017 and is uptrending. It has outperformed by 41.07% the S&P500.

Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on July, 24. They expect $0.03 EPS, up 50.00 % or $0.01 from last year’s $0.02 per share. NEO’s profit will be $2.42 million for 112.33 P/E if the $0.03 EPS becomes a reality. After $0.02 actual EPS reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts 50.00 % EPS growth.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 2 analysts covering NeoGenomics (NASDAQ:NEO), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. NeoGenomics had 2 analyst reports since April 16, 2018 according to SRatingsIntel. First Analysis downgraded the shares of NEO in report on Wednesday, May 2 to “Equal-Weight” rating. The stock has “Outperform” rating by BTIG Research on Monday, April 16.

More news for NeoGenomics, Inc. (NASDAQ:NEO) were recently published by:, which released: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018.‘s article titled: “NeoGenomics to Participate In Two Upcoming Investor Conferences” and published on May 25, 2018 is yet another important article.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $1.09 billion. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

NeoGenomics, Inc. (NASDAQ:NEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: